ERBB2 and breast carcinoma: Subtype-specific analyses indicated that Gp-R was more likely to achieve pCR across ER + HER2−, ER ± HER2 + , and ER−HER2− breast cancer subtypes, as well as with anthracycline and anthracycline-taxane therapies (odds ratios ranging from 3.23 to 5.72, Fig. 1B).